with submissions to the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency ...

Global health is likely to be radically altered with Donald Trump in the White House. For starters, the president-elect has ...

While Várhelyi praised the European Medicines Agency (EMA) in his hearing last week, MEPs are still pointing to Budapest’s approach to the Covid-19 pandemic — when it was the only EU country to ...

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...